151 related articles for article (PubMed ID: 17409949)
1. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.
Kishi K; Nakata K; Yoshimura K
J Thorac Oncol; 2006 Sep; 1(7):733-4. PubMed ID: 17409949
[No Abstract] [Full Text] [Related]
2. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
Garfield D
J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
[No Abstract] [Full Text] [Related]
3. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
4. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
5. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Garfield DH
J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
[No Abstract] [Full Text] [Related]
6. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
[No Abstract] [Full Text] [Related]
7. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
Gridelli C; Maione P; Galetta D; Rossi A
J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020
[No Abstract] [Full Text] [Related]
8. A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.
Hotta K; Kiura K; Shirahige A; Takata S; Takigawa N; Tabata M; Watanabe H; Tanimoto M
Acta Oncol; 2009; 48(3):471-3. PubMed ID: 18855159
[No Abstract] [Full Text] [Related]
9. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Shih JY; Gow CH; Yang PC
N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
[No Abstract] [Full Text] [Related]
10. Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Morabito A; Costanzo R; Rachiglio AM; Pasquale R; Sandomenico C; Franco R; Montanino A; De Lutio E; Rocco G; Normanno N
J Thorac Oncol; 2013 Jul; 8(7):e59-60. PubMed ID: 23774386
[No Abstract] [Full Text] [Related]
11. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
12. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
[No Abstract] [Full Text] [Related]
13. Pulmonary fibrosis in a patient treated with erlotinib.
Bach JP; Kiessling AM; Kleinhans A; Faoro C; Gorg C; Riera-Knorrenschild J; Schwella N; Wagner HJ; Neubauer A
Onkologie; 2006 Jul; 29(7):342-3. PubMed ID: 16874020
[No Abstract] [Full Text] [Related]
14. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Wong AS; Seto KY; Chin TM; Soo RA
J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
[No Abstract] [Full Text] [Related]
15. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
16. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
18. Gefitinib is also active for carcinomatous meningitis in NSCLC.
Kim MK; Lee KH; Lee JK; Choi JH; Hyun MS
Lung Cancer; 2005 Nov; 50(2):265-9. PubMed ID: 16024135
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
